Published • loading... • Updated
Kaigene Enters Into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan
The agreement gives Taisho exclusive Japan rights to KG006, which Kaigene says could speed regulatory approval and patient access.
- On Thursday, Kaigene Inc. announced an exclusive licensing agreement with Taisho Pharmaceutical Co., Ltd. to develop and commercialize KG006, a next-generation FcRn inhibitor, in Japan.
- Under the agreement, Kaigene receives a $5 million upfront payment and is eligible for up to $22 million and ¥57.5 billion, approximately $351 million, in milestone payments plus tiered royalties.
- This partnership establishes a three-way clinical development framework with Celltrion Inc., which holds global rights outside Japan and Greater China, to accelerate the Multi-Regional Clinical Trial Phase 3 study.
- Taisho brings significant expertise in autoimmune therapeutics, having successfully developed and commercialized Nanozora, an anti-TNF VHH antibody for Rheumatoid Arthritis treatment in Japan.
- Minjae Shin, Chief Executive Officer and Founder of Kaigene, Inc., stated integrating Taisho completes a formidable "One Team" aimed at fast-tracking clinical trials and maximizing KG006's potential.
Insights by Ground AI
38 Articles
38 Articles
Ember LifeSciences and Alfresa Corporation Enter into Capital and Business Alliance to Improve the Quality of the Pharmaceutical Cold Chain in Japan
Ember offers Japanese market pharmaceutical transportation solution integrating temperature control, visualization of transportation status and traceability
·Billings, United States
Read Full Article
Ember LifeSciences and Alfresa Partner to Distribute Temperature-Sensitive Pharmaceuticals in Japan
Ember LifeSciences and Alfresa, Japan’s largest pharmaceutical wholesaler, have entered into a strategic alliance to manage the distribution of temperature-sensitive medical products. The partnership addresses the rising demand for cold chain logistics as the market for biologics and specialty pharmaceuticals continues to expand in Japan. The collaboration integrates Ember LifeSciences’ specialized cold chain capabilities with
Coverage Details
Total News Sources38
Leaning Left5Leaning Right2Center27Last UpdatedBias Distribution79% Center
Bias Distribution
- 79% of the sources are Center
79% Center
15%
C 79%
Factuality
To view factuality data please Upgrade to Premium
